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Abstract
Background: Care for patients with thyroid nodules is complex and multidisciplin-
ary, and research demonstrates variation in care. The objective was to develop clini-
cal guidelines and quality metrics to reduce unwarranted variation and improve
quality.
Methods: Multidisciplinary expert consensus and modified Delphi approach.
Source documents were workflow algorithms from Kaiser Permanente Northern
California and Cancer Care of Ontario based on the 2015 American Thyroid Asso-
ciation management guidelines for adult patients with thyroid nodules and differen-
tiated thyroid cancer.
Results: A consensus-based, unified preoperative, perioperative, and postoperative
workflow was developed for North American use. Twenty-one panelists achieved
consensus on 16 statements about workflow-embedded process and outcomes met-
rics addressing safety, access, appropriateness, efficiency, effectiveness, and patient
centeredness of care.
Conclusion: A panel of Canadian and United States experts achieved consensus on
workflows and quality metric statements to help reduce unwarranted variation in
care, improving overall quality of care for patients diagnosed with thyroid nodules.
KEYWORDS
differentiated thyroid carcinoma, quality of care, thyroid, thryoidectomy, thyroid
nodules
1 | INTRODUCTION
Palpable thyroid nodules occur in 5% of women and 1% of
men in iodine-sufficient areas.1,2 Their prevalence varies
with detection mode and increases with age—2%-6% by pal-
pation versus 19%-68% by ultrasound.3,4 Among all thyroid
nodules, 7%-15% are malignant, and the proportion varies
with age, sex, radiation exposure, family history, and other
factors.5–10 At least 94% of thyroid carcinomas are differen-
tiated thyroid cancer (DTC), primarily papillary thyroid car-
cinoma (PTC), and follicular thyroid carcinoma.11,12 The
annual incidence of thyroid cancer per 100 000 person has
increased from 4.6 in 1974-1977 to 14.4 in 2010-2013.13 In
the United States, 64 300 cases were predicted to be diag-
nosed in 2016.14 This figure is largely attributable to inci-
dentally detected subclinical disease.15–17 Hence, by 2019,
PTC is estimated to become the third most common cancer
among US women and has an associated annual cost
between $18 and $21 billion dollars.12 Thyroid nodule eval-
uation and treatment varies substantially in the United States,
with thyroidectomy rates ranging from 29 to 139 per 100 000
Medicare beneficiaries. The patterns of heterogeneity in thyroid
care appear unrelated to health care access, physician supply,
or socioeconomic status.18
Reducing unwarranted variation in disease management
is pivotal for optimizing the quality of care for individuals
diagnosed with thyroid nodules. Clinical practice guidelines
(CPGs) are one way to achieve this goal, providing guidance
that helps health care professionals and patients make appro-
priate health care decisions together. Clinical guideline
development is accomplished by synthesizing clinical evi-
dence, but their creation is not always carried out with the
end user in mind, which can make them difficult to use.19,20
Clinical algorithms, which are tools created from guidelines,
can enhance implementation by organizing complex narra-
tives and decision trees into a format that allows easier use
in everyday practice.21 In 2015, the American Thyroid Asso-
ciation (ATA) released revised management guidelines for
adult patients with thyroid nodules and DTC.5 The ATA
guidelines inspired independent simultaneous initiatives at
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Kaiser Permanente Northern California (KPNC) and Cancer
Care of Ontario (CCO) to codify them into algorithms.
Here, we outline the work and results of our cross-national
harmonization through a multidisciplinary consensus process
with representatives from key professional medical organiza-
tions involved in thyroid care in the United States and Canada.
The resulting unified workflow algorithms are designed to
optimize implementation of the ATA guidelines and for stan-
dardization of care. We selected process and outcomes metrics
through a modified Delphi process that correspond to the
workflow, as well as other key aspects of thyroid perioperative
care. These metrics can be used to support measurement of
adherence. The objective is to reduce unwarranted variations
in care for patients diagnosed with thyroid nodules.
2 | MATERIALS AND METHODS
2.1 | Harmonizing existing workflow algorithms
In the first phase, a subgroup of authors (C.M., J.I., and
G.R.) compared the contents of the Thyroid Cancer Diagno-
sis Pathway Map designed by CCO to the KPNC workflows.
Although the formatting was different, the content was very
similar in both algorithms and both included a color guide to
assign responsibility by specialty for each step along the care
pathway. The more compact KPNC format was selected as
the basis for the remaining consensus building process.
In the second harmonization phase, the workflow algo-
rithms were shared with the entire author panel and reviewed
over a series of meetings to gather input and create consen-
sus regarding the content. In the third and final phase, each
figure was reviewed by a subgroup of authors responsible
for the associated content for the purpose of creating narra-
tive summaries to support the quality metric statements.
After additional editing, each of the three figures was
brought back to the entire author panel for approval.
2.2 | Development of quality statements—Modified
Delphi method
2.2.1 | Selection of panel members
Panel members were selected to represent surgeons and
endocrinologists from North America and major professional
societies, including the American Head and Neck Society
(AHNS), American Academy of Otolaryngology-Head and
Neck Surgery, American Association of Endocrine Sur-
geons, ATA, American Association of Clinical Endocrinolo-
gists (AACE), and American College of Surgeons.
2.2.2 | Statement selection and related evidence
A subgroup of 10 coauthors (B.M., C.M., E.M., G.R., J.M.,
J.J.S., J.I., L.D., M.O., and L.G.T.M.) identified topics for
statements that would undergo consensus development, tak-
ing into consideration existing and planned quality metrics
at KPNC and COO.22,23 Twelve metrics common to the two
systems were included, along with five others (antibiotic
use, 30-day mortality rates, postoperative voice evaluation,
preoperative calcium level, and outpatient surgery) that were
unique to KPNC. The subgroup had considered an abbrevi-
ated list of metrics but included all 17 to enhance tailoring to
local care settings. After discussion among panel members,
the quality metric for outpatient surgery was dropped
because the chosen metric of length of stay (LOS) incorpo-
rated same-day surgery. Based on the proposed metrics, can-
didate statements were proposed in alignment with the
Institute of Medicine's principles of health care quality, with
the goal of addressing safety, access, appropriateness, effi-
ciency, effectiveness, and patient centeredness.
Candidate statements and a concise summary of associ-
ated evidence from the relevant guideline were distributed to
panel members. The following evidence appraisal systems
had been used during ATA guideline development (the source
document for the evidence).5 For therapeutic interventions,
the task force had used the American College of Physicians
Grading System for the appraisal of evidence on therapeutic
interventions.24 For appraisal of evidence on diagnostic tests,
prognostic tests, and risk stratification systems, the task force
had devised a system based on the STARD, GRADE,
QUADAS-2, and other scales.25–29 These systems were com-
bined with expert opinion reached by consensus if there were
insufficient data to guide recommendations.
Definitions and refinements for the proposed statements
were drawn from guidelines produced by the AACE and
American College of Endocrinology clinical review of post-
operative hypoparathyroidism30 and KPNC and CCO docu-
ments. The AACE guidelines used for our process had also
been developed through established protocols and assess-
ments of evidence to support guideline development.31–34
2.2.3 | Consensus process
Consensus was assessed in two rounds. In the first round,
the entire expert panel rated 16 statements. The first author
sent the link to an online survey (www.surveymonkey.com,
San Mateo, California) containing candidate statements and
brief instructions to panel members through e-mail. Mem-
bers of the expert panel reviewed proposed statements and
independently rated their level of agreement or disagreement
with each, using a Likert scale ranging from 1 (Strongly Dis-
agree) to 9 (Strongly Agree), with 5 representing a “Neutral”
response. Panelists could also provide free-text comments
for further discussion, which were logged. Survey results
were tracked, summarized, and interpreted at each stage.
During a subsequent teleconference, panel members dis-
cussed the results, focusing on statements that had engen-
dered comments, a desire for more detail, or suggestions for
refinement. Discussion revealed varying interpretations of
and suggestions for rewording 10 statements. Consequently,
a subgroup (C.M., L.D., J.S., J.I., and G.R.) modified
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TABLE 1 Results of panel ratings
Statement Panel round one Median DI Panel round two Median DI
Preoperative care
1 Clinic and OR access should be readily available to all
patients in a timely manner. Monitoring access to specialty
consultation and to scheduling of elective surgery reflects
the degree of access to care.
7.00 0.22 Monitoring access to specialist consultation and
elective surgery may help determine whether clinical
care is readily available to patients.
7.00 0.22
2 Risk stratification utilizing thyroid sonography with survey of
the cervical lymph nodes should be performed in all
patients with known or suspected thyroid nodules.
9.00 0.29 --
3 In consideration of the recommendation by the ATA to limit
surgery on foci that are less than 1 cm, monitoring of the
volume of surgeries per 100 k performed for DTC in a
community can be a proxy for possible unnecessary
surgeries.
5.00* 0.52 The institutional- or system-wide annual rate of
thyroidectomies performed for DTC in a nodule with
a maximum diameter less than 1 cm should be
monitored.
7.00 0.16
4 Utilization of Bethesda classification is important for
consistent reporting of thyroid cytopathology.
9.00 0.00 --
5 At times, there may be concurrent parathyroid disease not
appreciated during the work up of a thyroid nodule. To
avoid the potential complications associated with
reoperations, it is suggested to screen for
hyperparathyroidism with a serum calcium level prior to
thyroid surgery.
7.00 0.29 To avoid the potential complications associated with
reoperations, it is suggested to obtain a parathyroid
hormone or serum calcium level prior to thyroid
surgery.
7.00 0.16
6 Surgical volume is a positive indicator of more efficient and
effective care. Thyroid surgeons should perform a
minimum of at least 10 cases per year.
7.00 0.22 --
Perioperative management
7 To have an understanding of true postoperative voice status
following thyroid surgery, a preoperative assessment of the
voice and possible laryngeal exam if there a voice issue or
previous neck or chest surgery is recommended.
9.00 0.19 --
8 Antibiotics are not usually recommended for clean surgeries
including thyroidectomy. Monitoring for antibiotic usage is




9 Monitoring postoperative serum thyroglobulin levels for
patients on thyroid hormone therapy or after TSH
stimulation is helpful in assessing the persistence of
disease or thyroid remnant and predicting future disease
recurrence.
9.00 0.29 --
10 Staging for all patients with DTC is important for the value it
brings in predicting disease mortality and driving decision
making in treatment and surveillance.
8.00 0.29 The AJCC staging and dynamic risk stratification
systems for DTC bring value when predicting
disease mortality or recurrence, as well as for guiding
decisions about treatment and surveillance.
7.50 0.16
11 Patients should have their voice and/or vocal-folds evaluated
in the postoperative period following any thyroid surgery.
9.00 0.13 Patients should have their vocal-fold function evaluated
between 2 wk and 2 mo after thyroid surgery.
8.50 0.29
12 Patients should have their serum calcium checked to assess
for permanent hypoparathyroidism following total or
completion thyroidectomy.
9.00 0.00 For patients who require high-dose vitamin D
supplementation at 12 mo or longer following total
or completion thyroidectomy, a calcium and/or PTH
level should be checked.
7.00 0.56
13 Mortality rates following thyroid surgery are very low.
Monitoring of these rates is still important to recognize rare
sentinel events such as hematoma that might happen
following thyroid surgery.
8.00 0.29 Mortality rates should be monitored after thyroid
surgery
8.50 0.24
14 Readmission rates monitored within the first 30 days
following thyroid surgery are a reasonable proxy for
possible significant complications after surgery.
7.00 0.52 Readmission rates within the first 30 d following
thyroid surgery is a potential proxy for some
complications after surgery.
8.00 0.29
15 Monitoring for unplanned return to the OR following
thyroidectomy is a good indicator of serious postoperative
complications such as hematomas.
7.00 0.22 Reoperation rate during the first 30 d is an indicator for
some postoperative surgical complications after
thyroid surgery (eg, hematoma, vocal cord paralysis,
and aspiration requiring medialization).
8.00 0.26
16 More thyroid surgery is now being performed same day in an
outpatient venue. Monitoring of average LOS is a good
proxy for resource management in terms hospital stays.
5.00 0.52 The average LOS is a good proxy for perioperative
resource management and allows comparisons to be
made to other surgical and medical patients.
7.00 0.22
--, No edits made after the first round.
a Nonconsensus.
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10 statements for review in the second round (Table 1), clari-
fying areas prone to variable interpretation and ensuring
statements were suitable for most practice settings. Six state-
ments were neither revised nor reviewed again. The results
were shared in a second telephone conference, and the final
list of statements was sorted into preoperative, perioperative,
and postoperative periods.
The RAND/UCLA Appropriateness method,35,36 a mod-
ified Delphi method,37,38 was used to quantitatively assess
for panel consensus. A similar approach has been used in
expert panels in other fields.39,40 The consensus criteria
required a median score ≥ 7.0, representing a response of
“Agree” on the Likert scale. In addition, a disagreement
index (DI) was calculated, defined as interpercentile range/
interpercentile range adjusted for symmetry, with a value
>1.0 indicating disagreement.35,40 Calculations and data
analysis were performed by a Kaiser Permanente analytic
team using Microsoft Excel 2016 (Redmond, Washington).
3 | RESULTS
3.1 | Workflow algorithm harmonization
The workflow algorithms were modified to include the
American College of Radiology Thyroid Imaging Reporting
and Data System (TIRADS), in addition to the ATA pattern
recognition risk stratification system.41 Minor revisions were
made to the content within specific nodes of the figure by
the leads responsible for each section (R.M.H., M.O., and
R.W.), along with visual changes to enhance the presenta-
tion. The resulting workflow algorithms address preopera-
tive (Figure 1), perioperative (Figure 2), and postoperative
(Figure 3) management of patients diagnosed with thyroid
nodules.
3.2 | Modified Delphi results
Twenty-one panelists completed both rounds of surveys. In
the first round, consensus was achieved on 14 statements. At
the completion of the second round, consensus was achieved
on 16 statements; two statements that did not reach consen-
sus in the first round did so in the second. Table 1 provides
the results for both rounds of panel ratings.
3.3 | Preoperative management
The four essentials of preoperative thyroid nodule care are:
(1) appropriate selection of patients for evaluation, (2) com-
prehensive anterior and lateral neck imaging with ultra-
sound, (3) careful clinical decision making in accordance
with existing guidelines (who to biopsy, how to interpret
cytology/molecular testing, and how to incorporate clinical
history, imaging, and laboratory studies into surgical plan-
ning), and (4) selection of a competent thyroid cancer sur-
geon (Figure 1).
Statement 1. Monitoring access to specialist consulta-
tion and elective surgery may help determine whether
clinical care is readily available to patients. For patients
diagnosed with euthyroid nodules, access to specialist con-
sultation and elective surgery varies widely between the
United States and Canada.42 Patients waiting for thyroid sur-
gery for lengthy periods of time may experience unnecessary
stress and anxiety.43 The panel did not make a recommenda-
tion about the upper limit of wait times for elective surgery.
This statement supports setting-specific and locally relevant
definitions of delayed access and improvement initiatives to
reduce delays.
Statement 2. Risk stratification utilizing thyroid
sonography with survey of the cervical lymph nodes
should be performed in all patients with known or sus-
pected thyroid nodules. The purpose of ultrasound-based
risk stratification is to distinguish between thyroid nodules
with the greatest and least potential for malignancy, which
drives the need for either biopsy or observation. Appropriate
ultrasound imaging is the foundation of risk stratification.5 It
is indicated in the presence of palpable thyroid nodules or
the incidental discovery of thyroid pathology by unrelated
imaging studies. Risk factors, such as a history of childhood
or adolescent radiation exposure, a family history of thyroid
cancer in multiple first-degree relatives, or certain clinical
syndromes that have associated thyroid pathology, may
drive decision making around fine needle aspiration (FNA)
biopsy of a lesion that is smaller than the size described by
the ATA guidelines.
When criteria for neck imaging are met, state-of-the-art
thyroid nodule care requires ultrasound of the entire anterior
and lateral neck, including: (1) central and lateral lymph
nodes, (2) pyramidal lobes, (3) thyroglossal duct tract ele-
ments, and (4) relationships between thyroid nodules and
surrounding strap muscles, vascular structures, trachea/
esophagus, and posterior structures (the bone, muscle, and
recurrent laryngeal nerve [RLN]).44
The ATA thyroid nodule risk stratification5 and radio-
logic TIRADS41 systems incorporate clinical and imaging
information to provide guidance for clinicians as to which
thyroid nodules require observation, biopsy by FNA, or nei-
ther. Figure 1 combines the ATA 2015 and TIRADS 2017
classifications in the second and third row of cells: (1) ATA
benign and TIRADS 1 and 2 nodules may be observed,
(2) ATA very low to high suspicion and TIRADS 3-5 nod-
ules should undergo FNA depending on nodule size, with
biopsy cut points differing between the two systems, and
(3) all ATA very low to high cancer suspicion and TIRADS
3-5 nodules below FNA size cut points may be observed
with close follow-up or biopsied, based on patient preference
and risk factors.
Cross-sectional imaging using CT with contrast or MRI
should be considered when planning surgery if there are
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abnormal nodes at the limits of the sonogram or extensive
nodal disease or the primary tumor is very large or invasive.
Statement 3. The institutional or system-wide annual
rate of thyroidectomies performed for DTC in a nodule
with a maximum diameter less than 1 cm should be mon-
itored. The indiscriminate use of high-resolution ultrasonog-
raphy has led to the diagnosis of many <1 cm nonpalpable
thyroid cancers, the vast majority of which would not other-
wise require clinical attention.45 The AHNS aims to mini-
mize the human and financial costs of unnecessary
evaluation and surgery by discouraging ultrasound imaging
in patients without risk factors for thyroid cancer and normal
physical examinations.
Statement 4. Utilization of Bethesda classification is
important for consistent reporting of thyroid cytopathol-
ogy. The Bethesda System for Reporting Thyroid Cytopa-
thology46 provides a diagnostic cytopathologic framework
for interpreting and reporting thyroid cancer risk based on
FNA of thyroid nodules.
For nodules qualifying for neither immediate surgery nor
dismissal, ongoing follow-up with clinical exam or ultra-
sound may be performed at 6-month to 2- to 3-year intervals,
depending on clinical context, and possible repeat FNA at
3 months after initial aspiration for Bethesda I or longer,
depending on ultrasound findings.47
Statement 5. To avoid the potential complications
associated with reoperations, it is suggested to obtain a
parathyroid hormone or serum calcium level prior to
thyroid surgery. As intraoperative parathyroid hormone
(ioPTH) levels are being used to obtain a baseline at the time
of a total thyroidectomy and/or at the conclusion of surgery
to better direct the management of potential postoperative
hypoparathyroidism,48 an abnormally and unexpectedly high
ioPTH level will raise the question of an incidental parathy-
roid adenoma. Incidental parathyroid adenomas that are
diagnosed at the time of thyroid surgery are reported to
occur in 0.2%-4.5% of cases.49 Obtaining a parathyroid hor-
mone (PTH) level or a serum calcium level should be con-
sidered prior to surgery as a useful screening lab to reduce
the unexpected incidentaloma finding or need to reoperate
on a patient who may have concomitant disease. Guidelines
for appropriate management of incidentally identified para-
thyroid adenomas should be closely followed.
Statement 6. Surgical volume is a positive indicator of
more efficient and effective care. Numerous studies docu-
ment associations between higher surgeon volumes for thyroid
procedures, better outcomes, and lower costs.50–54 Once com-
plete evaluation of a thyroid nodule suggests a need for sur-
gery, management by a high-volume thyroid cancer surgeon is
associated with lower postoperative complication rates.52
3.4 | Perioperative management
The surgical team must educate the patient about the surgical
risks of thyroidectomy, including voice alteration and
parathyroid dysfunction (Figure 2). The team should also
formulate a comprehensive care plan with anesthesia and
perioperative nursing care teams.
Patients should undergo a total or near-total thyroidec-
tomy, unless contraindicated, if there is a preoperative diag-
nosis of DTC and any of the following features: lesion
>4 cm, aggressive histologic subtypes, clear extrathyroidal
extension, or preoperatively identified nodal metastases. The
surgeon may offer less than total thyroidectomy for defini-
tive management to patients with cancers that are between
1 and 4 cm in size without obvious extrathyroidal extension
or preoperatively identified nodal metastasis. The surgeon
may consider total thyroidectomy in patients in whom there
are contralateral nodules or in patients in whom postopera-
tive radioactive iodine ablative therapy and/or whole-body
scanning and thyroglobulin-based follow-up protocols may
be beneficial after a discussion of risks, benefits, and other
clinical considerations.
Therapeutic central compartment (levels VI and VII)
nodal dissection should be carried out in patients with either
preoperative or intraoperative evidence of gross or radio-
graphically diagnosed lymphadenopathy in these regions.
Prophylactic central compartment neck dissection should be
considered for patients with T3 or T4 cancers or in the pres-
ence of lateral neck metastasis (N1b). Bilateral prophylactic
central neck dissection in the absence of either preoperative
or intraoperative lymphadenopathy is generally not recom-
mended as a result of a higher risk of postoperative compli-
cations that include hypoparathyroidism and RLN injury.
Thyroid lobectomy without central compartment neck
dissection should be considered in (cN0) patients with non-
invasive T1 or T2 cancers or minimally invasive follicular
carcinoma. Any intraoperative findings that suggest more
advanced disease should guide surgical decision making.
A selective therapeutic lateral neck dissection should be
performed for patients with DTC and clinically apparent
N1b disease. Levels II through V should be considered for
dissection, although removal of level Va may be omitted in
the absence of clinically or radiographically apparent nodes
at this level. When nodes are clinically or radiographically
abnormal, they should be included within the field of dis-
section even if located outside these regions.
The surgeon should offer completion thyroidectomy to
patients who have undergone a lobectomy when final patho-
logic features would have mandated total thyroidectomy had
they been known preoperatively. Dissection of central com-
partment lymph nodes on the previously operated side is
generally not necessary without clinical or radiographic evi-
dence of disease. Radioactive iodine (RAI) remnant ablation
can be considered in uncommon circumstances when com-
pletion thyroidectomy is contraindicated or if the patient
refuses further surgery.
Without exception, the recurrent (or nonrecurrent) laryn-
geal nerve should be identified and preserved during
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thyroidectomy. Care should also be taken to preserve the
external branch of the superior laryngeal nerve during thy-
roidectomy. Nerve monitoring during thyroid operations has
utility in patients with invasive or bulky primary or nodal
disease, with preoperative vocal-fold dysfunction, undergo-
ing revision surgery, or requiring bilateral thyroid surgery.
In the latter instance, neural monitoring can aid in nerve
identification as well as provide prognostic information
regarding neural function and is supported by the ATA,
AHNS, and American Academy of Otolaryngology-Head
and Neck Surgery guidelines.
Care should be taken to preserve the parathyroid glands
and their blood supply during thyroidectomy. When the
glands are removed or separated from their blood supply,
confirmed cancer-free grossly normal parathyroid tissue
should be autotransplanted into nearby muscle.
Statement 7. To have an understanding of true post-
operative voice status following thyroid surgery, a preop-
erative assessment of the voice and possible laryngeal
exam is recommended if there is a voice issue or previous
neck or chest surgery. Reported prevalence rates for voice
and swallowing symptoms in preoperative thyroidectomy
patients range from 11% to 88%.55 Although laryngopharyn-
geal reflux may account for many of these symptoms,55 all
patients scheduled for thyroid surgery should undergo preop-
erative screening for vocal fold dysfunction by voice or
laryngeal examination. Laryngoscopy is mandatory for
patients with abnormal findings on screening vocal examina-
tion, a history of previous neck or mediastinal surgery, or
bulky primary thyroid cancers or nodal disease.
Statement 8. Antibiotics are not usually recom-
mended for clean surgeries including thyroidectomy.
Monitoring for antibiotic usage is a way to evaluate qual-
ity of care and appropriate utilization. Systemic adminis-
tration of prophylactic antimicrobials has not been proven
effective in reducing surgical site infection rates in patients
undergoing clean procedures of the head and neck, including
thyroidectomies and is not recommended for routine use.56
3.5 | Postoperative management
Following thyroidectomy, important intraoperative findings
and details of postoperative care should be shared with the
patient and members of the multidisciplinary care team (Fig-
ure 3). These include: (1) anatomic findings during surgery,
including RLN and parathyroid status, (2) extent of primary
and regional nodal disease, including the presence of gross
residual disease and the presence of gross extrathyroidal
extension found at surgery, (3) postoperative status of the
voice and laryngeal exam, (4) postoperative serum calcium
and PTH levels and utilization of calcium and/or vitamin D
supplementation, and (5) the surgical pathology report.
Statement 9. Monitoring postoperative serum thyro-
globulin levels for patients on thyroid hormone therapy
or after thyroid-stimulating hormone (TSH) stimulation
is helpful in assessing the persistence of disease or thy-
roid remnant and predicting future disease recurrence.
The postoperative assessment by the endocrinologist or other
health care professional is important to measure postopera-
tive thyroid hormone levels and replace thyroid hormone as
indicated and to measure postoperative thyroglobulin
(Tg) and Tg antibody levels. The latter, along with surgical
pathology information, may guide decisions regarding post-
operative RAI ablation/treatment and additional imaging.
Following lobectomy, a decision may be made in some cases
to proceed with completion thyroidectomy to facilitate sys-
temic treatment with RAI, while surveillance alone after
lobectomy may be appropriate for certain low risk cancers in
other cases.
Statement 10. The American Joint Committee on
Cancer (AJCC) Staging and Dynamic Risk Stratification
systems for DTC bring value when predicting disease
mortality or recurrence, as well as for guiding decisions
about treatment and surveillance. A substantial proportion
of patients with DTC who are initially classified as interme-
diate and high risk have an excellent response to therapy and
become low risk for developing recurrent disease.57 Initial
risk estimates should be continually modified during ongo-
ing follow-up in a dynamic process of risk stratification. The
risk of cancer recurrence and disease-specific mortality may
change over time as a function of a specific patients' clinical
course and response to therapy.
Statement 11. Patients should have their vocal-fold
function evaluated between 2 weeks and 2 months after
thyroid surgery. Among nearly 28 000 patients undergoing
surgery for DTC or medullary thyroid cancer, postoperative
vocal cord paralysis occurred in 4.1% of instances.58 Voice
assessment should be based on the patient's subjective report
and the physician's objective findings. The panel selected
this time frame to avoid early assessment which might give
a false positive and a hard stop at 2 months because that
should be sufficient time for recovery and evaluation. An
abnormal voice evaluation should lead to a formal laryngeal
examination to assess vocal-fold mobility. Early detection of
vocal-fold motion abnormalities after thyroidectomy facili-
tates prompt intervention through vocal-fold medialization,
improving patient quality of life, and diminishing
aspiration risk.
Statement 12. For patients who require high-dose cal-
cium and vitamin D supplementation at 12 months or
longer following total or completion thyroidectomy, a
calcium and/or PTH level should be checked. Hypopara-
thyroidism is the most common complication of total thy-
roidectomy. Transient hypoparathyroidism occurs in 10% of
patients,59 and long-term outcomes for permanent hypopara-
thyroidism are measured by obtaining a PTH level longer
than 12 months after surgery. Consistent measurement
enables quality improvement.
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Statement 13. Mortality rates should be monitored
after thyroid surgery.
Statement 14. Readmission rates within the first
30 days following thyroid surgery is a potential proxy for
some complications after surgery.
Statement 15. Reoperation rate during the first
30 days is an indicator for some postoperative surgical
complications after thyroid surgery (eg, hematoma, vocal
cord paralysis, and aspiration requiring medialization).
Statement 16. The average LOS is a good proxy for
perioperative resource management and allows compari-
sons to be made to other surgical and medical patients.
In addition to RLN and parathyroid postoperative assess-
ment, other more global measures of perioperative quality of
care should be assessed. Multiple studies examining quality
and safety in thyroid surgery assess mortality,53,60–64 readmis-
sions with and without related data on reoperations,60,62,63,65–68
and LOS.50–53,64,69 Recommended quality metrics include mor-
tality rates, readmission rates, reoperation rates, and LOS in
hospital.
After considering comorbidities, available social support,
perioperative education, and proximity to emergency ser-
vices, same-day surgery may be a reasonable alternative to
overnight observation. Same-day surgery may not be possi-
ble in all clinical settings; consequently, the consensus group
selected LOS as a quality measure.
4 | DISCUSSION
Through broad multispecialty consensus representation from
societies in the United States and Canada, we developed
both workflows and quality statements for thyroid nodule
care. While CPGs articulate current best evidence and are
designed to reduce unwarranted variation in care that can
negatively affect quality outcomes, they often benefit from
efforts to support dissemination and implementation. The
workflows and statements presented here were created for
just that purpose and are intended for use across the range of
practice settings in North America.
4.1 | Implementing workflows and metrics
The integration of practice algorithms and quality metrics
such as those outlined here is a complex process. It requires
extensive collaboration between primary care providers, endo-
crinologists, thyroid surgeons, radiologists, nuclear medicine
physicians, radiation oncologists, and pathologists. At KPNC
and CCO, there was strong executive and leadership support
for implementation. At both organizations, it was a group pro-
cess: multidisciplinary teams and clinical champions worked
together to review the evidence over several months, meeting
bimonthly face-to-face for a full day to draft the workflows
and determine responsibilities for the various processes of
care. Compromises were required to respect the perspectives
of all involved specialties and to accommodate variations,
such as whether an endocrinologist, surgeon, or radiologist
performed ultrasound for risk stratification and assessment of
the thyroid, central, and lateral neck. Clinical champions then
took responsibility for helping with dissemination, addressing
concerns of end users in their specialty, urging their accep-
tance, and keeping them in active use.
Education was achieved through multiple in-person or
webinar continuing medical education (CME) sessions to
educate providers and obtain feedback. Robust discussion
occurred at these events, allowing resistance to change to be
expressed, acknowledged, and addressed. The feedback was
used to further refine the workflows during the rollout. As
implementation continued, additional CME events were
modified to reflect any changes in the workflows, reinforce
collaboration across the specialties, and demonstrate how
workflows are based on CPGs. At KPNC, an in-house medi-
cal journal published the workflows to facilitate their distri-
bution prior to the launch.23 In addition, after
implementation at KPNC, a performance improvement team
using tools based on human-centered design interviewed
physicians, nurses, and patients to further assure a collabora-
tive approach to the workflows and patient-centered decision
making regarding disposition following surgery, including
same-day discharge. CCO completed review in its 14 regions
before finalizing and distributing care paths though Commu-
nity of Practice events.
4.2 | Using quality metrics
This consensus statement includes quality metric statements,
because setting and reviewing local goals are key for driving
ongoing communication and improving quality of patient
care. The selected quality metric statements focus on key
concepts, and we explicitly did not define numerators,
denominators, or equations for each metric as we recognize
that individual sites should be able to adapt their use to local
constraints. Once integrated into practice, institutions may
wish to monitor the success of the implementation on a quar-
terly basis, providing feedback to individual surgeons and
measuring their institution against others. The metrics can
identify both superior performance as well as opportunities
for improvement. Institutions can also use the data to inform
patients about case volumes and outcomes.
5 | CONCLUSIONS
With these workflows and quality metric statements, the
AHNS Endocrine Section provides a simplified approach to
incorporate the 2015 ATA guidelines into the everyday man-
agement of thyroid nodules and DTC and have the potential
to improve quality and decrease unwarranted variations in
care. For implementation, we suggest that users create
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multidisciplinary teams in their local settings to review,
refine, implement, and sustain these practices.
DISCLAIMER
The ATA develops CPGs to provide guidance and recom-
mendations for practice areas concerning thyroid disease and
thyroid cancer. The Guidelines are not inclusive of all proper
approaches or methods or exclusive of others. The Guide-
lines do not establish a standard of care and specific out-
comes are not guaranteed. A guideline is not intended to
take the place of physician judgment in diagnosing and treat-
ment of patients. It is also not intended to serve as a basis to
approve or deny financial coverage for any specific thera-
peutic or diagnostic modality. Treatment decisions must be
made based on the independent judgment of health care pro-
viders and each patient's individual circumstances. The ATA
develops guidelines based on the evidence available in the
literature and the expert opinion of the task force in the
recent timeframe of the publication of the guidelines. Man-
agement issues have not been and cannot be comprehen-
sively addressed in randomized trials; therefore, the
evidence cannot be comprehensive. Guidelines cannot
always account for individual variation among patients.
Guidelines cannot be considered inclusive of all proper
methods of care or exclusive of other treatments reasonably
directed at obtaining the same results. Therefore, the ATA
considers adherence to its guideline to be voluntary, with the
ultimate determination regarding its application to be made
by the treating physician and health care professionals with
the full consideration of the individual patient's clinical his-
tory and physical status. In addition, the guideline concerns
the therapeutic interventions used in clinical practice and do
not pertain to clinical trials. Clinical trials are a separate mat-
ter, designed to research new and novel therapies, and the
guidelines are not necessarily relevant to their purpose.
Guideline development includes an identification of areas
for future study and research, indicating the focus for future
investigational therapy, based on the findings reviewed and
synthesized from the latest literature.
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